Abstract: The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.
Abstract: A biological composition intermixed with a polyampholyte protectant for direct implantation has a mixture of biologic material and a volume of polyampholyte protectant. The mixture of biologic material has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components, or whole cells or combinations of the non-whole cellular components and whole cells, wherein the mixture is compatible with biologic function. The volume of polyampholyte protectant is intermixed with the mixture of biologic material, wherein the polyampholyte protectant is a liquid of a polyamine polymer compound of carboxylated poly-lysine and wherein the polyampholyte protectant forms a three-dimensional bonding shroud externally enveloping each of the non-whole cellular components, if any, and each of the whole cells, if any, of the mixture of biologic material.
Type:
Grant
Filed:
December 11, 2017
Date of Patent:
November 2, 2021
Assignee:
Vivex Biologies Group, Inc.
Inventors:
Timothy Ganey, Shabnam Namin, Renaud Sicard, Wendy W. Weston
Abstract: An object of the invention is to provide a cartilage regenerative material that suppresses infiltration of fibrous soft tissue and brings about satisfactory cartilage regeneration, and a method for producing the cartilage regenerative material. Provided is a cartilage regenerative material including a porous body of a biocompatible polymer and a biocompatible polymer film, in which the porous body contains chondrocytes and cartilage matrix, and the cartilage matrix exists in a region of 10% or more of a region extending from the surface of the transplant face of the porous body to a depth of 150 ?m along the thickness.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
November 2, 2021
Assignees:
FUJIFILM Corporation, JAPAN TISSUE ENGINEERING CO., LTD.
Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
Abstract: The invention discloses a composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising from 40 to 80 wt % of fucosylated oligosaccharide(s), from 10 to 50 wt % of N-acetylated oligosaccharide(s), from 5 to 40 wt % of sialylated oligosaccharide(s) and from 0 to 20 wt % of precursor(s) of human milk oligosaccharide, for use in preventing and/or in treating necrotizing enterocolitis in infants and young children.
Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
Abstract: The present disclosure relates generally to methods of treatment of tissue prior to implantation. In one aspect, the methods of treatment include washing adipose tissue with detergents to improve the viability of adipose cells for implantation and/or to increase the amount of viable adipose cells per volume of tissue for implantation.
Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from placental tissue. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.
Type:
Grant
Filed:
April 11, 2018
Date of Patent:
August 3, 2021
Assignee:
Vivex Biologics Group, Inc.
Inventors:
Timothy Ganey, Wendy W. Weston, Gaëtan Jean-Robert Delcroix
Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from placental tissue. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.
Type:
Grant
Filed:
July 27, 2015
Date of Patent:
August 3, 2021
Assignee:
Vivex Biologics Group, Inc.
Inventors:
Timothy Ganey, Wendy W. Weston, Gaëtan Jean-Robert Delcroix
Abstract: The present invention provides a device for assaying living cells comprising a substrate, wherein the substrate comprises one or more tethering molecules which adhere to the substrate and are capable of interacting with cell membranes of the cells, wherein the cells maintain a free-floating, non-adherent character when bound to the one or more tethering molecules.
Type:
Grant
Filed:
October 7, 2015
Date of Patent:
July 6, 2021
Assignees:
UNIVERSITY OF MARYLAND, COLLEGE PARK, UNIVERSITY OF MARYLAND, BALTIMORE
Inventors:
Stuart Martin, Christopher M. Jewell, James I. Andorko, Elisabeth Lily Sooklal, Rebecca Whipple Bettes, Kristi Chakrabarti
Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
Abstract: The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.
Abstract: An object of the present invention is to provide a medium that comprises fewer protein components and enables the maintenance of pluripotent stem cells in an undifferentiated state. The culture medium for pluripotent stem cells comprises a GSK3? inhibitor (A) and a DYRK inhibitor (B).
Type:
Grant
Filed:
March 25, 2015
Date of Patent:
May 25, 2021
Assignee:
KYOTO UNIVERSITY
Inventors:
Kouichi Hasegawa, Shinya Yasuda, Hosein Shahsavarani, Noriko Yoshida
Abstract: A system for seeding therapeutic active ingredients (TAIs) onto a porous scaffold includes a first chamber for accommodating the scaffold, a TAI storage device for storing TAIs, at least one second chamber for storing TAI media, and a gas inlet for receiving gas from a compressed source. A flow circuit is coupled to the first chamber, the TAI storage device, the second chamber and the gas inlet for delivering the TAIs, the TAI media and the gas to the scaffold. A pump pumps at least one of the TAIs, the TAI media and the gas in the flow circuit. The system also includes a processor that regulates the delivery of the TAIs, the TAI media and the gas to the scaffold via a plurality of valves.
Abstract: A scaffold is provided, the scaffold comprising: at least one inlet tube; at least one outlet tube; and a plurality of porous elongated microtubes, wherein each one of said porous elongated microtube has an inner diameter of 5-100 micrometers, wherein said plurality of elongated microtubes extend from said at least one inlet tube to said at least one outlet tube and is in fluid communication thereto, Further provided is a method for producing and using the scaffold, such as for tissue engineering.
Type:
Grant
Filed:
September 18, 2016
Date of Patent:
March 9, 2021
Assignees:
BONUS THERAPEUTICS LTD., HEALTH CORPORATION OF GALILEE MEDICAL CENTER
Abstract: The present disclosure provides a non-autologous product that is a mixture of two or more cells or tissue cultures of fibroblast, or extracts from cultures, or media cultures, isolated from separate individuals, either homogeneous or heterogeneous. The cells or factors are blended together in a product that imparts desired characteristics to the skin of a recipient who is not a source of the mixture. The present disclosure also relates to methods of making and using and/or culturing the fibroblasts including to optimize the potency of the mixture to impart one or more the desired characteristics to the skin of a recipient.
Type:
Grant
Filed:
November 14, 2014
Date of Patent:
March 9, 2021
Assignee:
Dermaforce Holdings, LLC
Inventors:
Jonah Shacknai, Mitchell S. Wortzman, David H. McDaniel
Abstract: The present invention relates to a composition comprising at least one human milk oligosaccharide and/or a precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants or young children born by C-section.
Abstract: A substrate for culturing cells that includes at least one fiber scaffold adapted to be contained within a disposable or non-disposable bioreactor, wherein the fiber scaffold further includes polymer fibers that have been created by electrospinning, and wherein the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.